The 2021 American Society of Hematology (ASH) Annual Meeting and Exposition was held from December 11 to 14 in Atlanta, Georgia.
In this podcast, Christopher Flowers, MD, discusses the research presented at the meeting, including new treatments for non-Hodgkin lymphoma, advances in immunotherapy, and a session on improving equity, diversity, and inclusion in cancer clinical trials.
Results from the POLARIX phase III clinical trial, which studied whether substituting the targeted therapy drug polatuzumab vedotin (Polivy) in place of the chemotherapy drug vincristine (Vincasar) in a common standard treatment for diffuse large B-cell lymphoma (DLBCL) lengthened the time it took for the cancer to grow or spread. [4:15]
An overview of a new type of immunotherapy called bispecific antibodies, which bring T cells into the tumor to attack the lymphoma cells. [8:58]
An overview of a session discussing ways to improve clinical trial design to increase equity, diversity, and inclusion in clinical trials and change eligibility criteria so more people with cancer can participate in clinical trials. [9:34]
Dr. Flowers is the Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center and was appointed Division Head ad interim of Cancer Medicine in August 2020. Dr. Flowers is the 2022 Cancer.Net Associate Editor for Lymphoma.
Disclosure information for Dr. Flowers can be found in his biography linked to above.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
Cancer.Net podcasts are edited for length and content.